Clinical trials: Brief Psychotic Disorder
Schizophrenia, Psychotic Disorders
A Brief Community Linkage Intervention for Dually Diagnosed Individuals
Surveys suggest that up to 80% of veterans with a persistent mental illness have a co-occurring substance use disorder. Substance abuse among this population is problematic and often results in poor engagement in treatment and…
- Conditions
- Schizophrenia, Psychotic Disorders, Substance-Related Disorders, Bipolar Disorder
- Trial name
- TLC (NCT00137267)
- Testing
- Time limited case management, Health Education
- Where
- 2 sites in United States
- Volunteers
- 102 people
- Sponsor
- US Department of Veterans Affairs
Psychosis, Alcohol Use Disorder
Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis
Psychotic disorders impact 4.6 people per 1000 globally, with approximately 1.5 million Canadians affected. The age of onset for psychotic disorders often begin during the critical years of youth and early adulthood, resulting in…
- Conditions
- Psychosis, Alcohol Use Disorder, Cannabis Use Disorder
- Trial name
- NCT07056894
- Testing
- Action-Based Cognitive Remediation
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Nova Scotia Health Authority
Delusional Disorder, Brief Psychotic Disorder
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis
FEEL-GOOD is a prospective multi-site single-blinded randomized controlled trial in young inpatients with acute early psychosis. Participants are randomized 1:1 to FEEL-GOOD plus treatment as usual (TAU) or TAU alone.
- Conditions
- Delusional Disorder, Brief Psychotic Disorder, Schizophreniform Disorder, Schizophrenia / Schizoaffective Disorder
- Trial name
- FEEL-GOOD (NCT07645443)
- Testing
- FEEL GOOD, Treatment as Usual (TAU)
- Where
- 8 sites in Germany
- Volunteers
- 252 people
- Sponsor
- Stephanie Mehl
Psychosis
Testing the Effectiveness of The Welcome Basket Intervention
The investigators propose to examine the effectiveness of a brief intervention that might better facilitate the transition into the community for people with schizophrenia or bipolar disorder with psychotic features.
- Trial name
- NCT02946255
- Testing
- Welcome Basket (WB), Welcome Basket Brief (WBbr), Treatment As Usual
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
A Physical Dependence Study in Schizophrenia
The purpose of this study is to determine whether or not people with schizophrenia who take LY2140023 become physically dependent on it, and experience a series of symptoms such as craving to have the drug when they stop using…
- Trial name
- NCT01452919
- Testing
- LY2140023
- Where
- 10 sites in United States, Greece
- Volunteers
- 123 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia, Schizoaffective Disorder
Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia
This study will provide information regarding dopamine D2/D3 occupancy related with clinical/adverse effects in older people with schizophrenia and schizoaffective disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- NCT00825045
- Testing
- risperidone
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizophreniform Disorders
Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders
The goal of this clinical trial is to compare the efficacy of combined REHACOP + MCT alone in persons with nonaffective psychotic disorder in terms of recovery.
- Conditions
- Schizophrenia, Schizophreniform Disorders, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- CR+MCTp (NCT06423651)
- Testing
- Cognitive Remediation (REHACOP), Metacognitive Training (MCT)
- Where
- Spain
- Volunteers
- 160 people
- Sponsor
- Universitat Autonoma de Barcelona
NMDA Receptor Function
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects
The purpose of the study is 1. To establish the feasibility of fMRI studies of the interaction of guanfacine and ketamine. 2. To explore the possibility that guanfacine can ameliorate the negative effects of ketamine on…
- Trial name
- GuaKet (NCT01600885)
- Testing
- Guanfacine
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia, Cognitive Effect on Schizophrenic Patients
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone.
- Trial name
- CLARITY (NCT01363349)
- Testing
- CYP-1020, Risperidone
- Where
- 39 sites in India, Moldova and 1 more
- Volunteers
- 269 people
- Sponsor
- BioLineRx, Ltd.
Psychosis
Mindfulness RCT for Early Psychosis
Depressive mood and anxiety are prevalent in patients suffering from early psychosis. Treatments focused on these dimensions are rarely seen.
- Trial name
- MBIp (NCT02244970)
- Testing
- Mindfulness, Psychoeducation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The University of Hong Kong
Mental Disorder
Effect of a 'Rapid-Return-to-work Program' in Mild Mental Disorders.
This study is a pragmatic randomized controlled trial (RCT) evaluating the effect of brief versus short psychotherapy in subjects with substantial mental complaints.
- Trial name
- NCT04457635
- Testing
- Psychotherapy
- Volunteers
- 300 people
- Sponsor
- The Hospital of Vestfold
Schizophrenia
Efficiency Assessment of BREFORM. A Multicentric Stepped-wedge Randomized Control Trial.
In psychiatry, caregiver burden is associated with excess physical and psychological morbidity in relatives of patients with schizophrenic disorders Single or multi-family psychoeducation for caregivers of patients with…
- Trial name
- BREFORM (NCT05036590)
- Testing
- control group, Intervention group
- Where
- France
- Volunteers
- 206 people
- Sponsor
- Hôpital le Vinatier
Schizophrenia
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
- Trial name
- NCT03198078
- Testing
- Brexpiprazole (OPC-34712), Aripiprazole
- Where
- United States
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizotypal Disorder
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- PROBAS (NCT04874974)
- Testing
- Metacognitive and Defusion Training
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Schizophrenia, Delusional Disorder
Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia
The present study is a pilot single-blind randomized controlled therapy study. Its aim is to assess the efficacy of an emotion-focussed form of Cognitive behavior Therapy that focusses on emotional processes that are involved in…
- Conditions
- Schizophrenia, Delusional Disorder, Schizoaffective Disorder, Brief Psychotic Disorder
- Trial name
- CBT-E (NCT02787122)
- Testing
- CBT-E, Treatment as Usual
- Where
- 2 sites in Germany
- Volunteers
- 64 people
- Sponsor
- Philipps University Marburg
Mental Disorder, COVID
Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19
The study consists in a pragmatic superiority randomized controlled trial comparing different strategies of psychotherapy for professionals and students from essential services with high levels of emotional distress during the…
- Conditions
- Mental Disorder, COVID, Emotional Distress, Depression
- Trial name
- NCT04635618
- Testing
- Cognitive Behavioral Brief-Telepsychotherapy, Brief Interpersonal Telepsychotherapy, Telepsychoeducation
- Where
- Brazil
- Volunteers
- 999 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Sleep Disturbance, Insomnia
The CANabidiol Use for RElief of Short Term Insomnia
This study aims to investigate the effect of 50 mg and 100 mg per day oral CBD product versus a placebo over 8 weeks on insomnia severity in adults aged 18-65 years old with insomnia symptoms.
- Conditions
- Sleep Disturbance, Insomnia, Insomnia Type; Sleep Disorder, Insomnia, Transient
- Trial name
- CANREST (NCT05253417)
- Testing
- 50 mg Cannabidiol (CBD), 100 mg Cannabidiol (CBD)
- Where
- 2 sites in Australia
- Volunteers
- 208 people
- Sponsor
- Bod Australia
Akathisia
Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation
Akathisia is a movement disorder that is often a side effect of certain psychiatric drugs. People with akathisia are unable to sit or keep still, complain of restlessness, fidget, rock from foot to foot, and pace.
- Trial name
- NCT00065286
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)